Author

Shari Kaiser

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5139917552

PA-358 Post-Infusion Immunophenotypic And Functional Characteristics Of Arlocabtagene Autoleucel (Arlo-Cel) In A First-In-Human (FiH), Phase 1 Trial In Relapsed/Refractory Multiple Myeloma (RRMM)

2026 · Sifiyya Ziyad, Kristina Jordahl, et al. · Clinical Lymphoma Myeloma & Leukemia

PA-145 Development of BMS-986453, a Dual-Targeting BCMA × GPRC5D Chimeric Antigen Receptor (CAR) for the Treatment of Multiple Myeloma

2026 · Kimberly Harrington, Jon C. Jones, et al. · Clinical Lymphoma Myeloma & Leukemia

Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma

2026 · Bruno Paiva, Irene Manrique, et al. · HemaSphere

Works count: 3

Citation count:

H-index:

I10-index: